Navigation Links
HemoShear Co-Founder Presents Recommendations for Funding of Breakthrough Technologies to U.S. House of Representatives Committee on Science, Engineering and Technology
Date:7/26/2013

CHARLOTTESVILLE, Va., July 26, 2013 /PRNewswire/ -- HemoShear, LLC, a leading developer of human-relevant systems for drug development and discovery, today announced that Dr. Brian R. Wamhoff, co-founder of HemoShear, was invited to present his recommendations on improvements to the U. S. government's Small Business Technology Transfer program to stimulate translation of new discoveries from academia to the marketplace.  Dr. Wamhoff's testimony was given on Wednesday at a hearing of the U.S. House of Representatives Committee on Science, Engineering and Technology for the purpose of guiding the draft of new legislation entitled "Innovative Approaches to the Technology Transfer Act of 2013".  Dr. Wamhoff was the only industry representative selected to present to the Committee. 

(Logo: http://photos.prnewswire.com/prnh/20120416/PH86899LOGO )

Dr. Wamhoff is currently Vice President of Research and Development for HemoShear LLC, a biotechnology research company that is transforming the productivity and success rates of new drug R&D in the pharmaceutical industry.  He was formerly Associate Professor at the University of Virginia Department of Medicine, Cardiovascular Division, where he co-invented the HemoShear technology with Dr. Brett Blackman.  

"Having transitioned recently from academic researcher to entrepreneur, I benefitted from the creativity and resources that academic environments provide, while also encountering cultural challenges of translating a new technology from a university lab to a commercial enterprise.  My fellow academic researchers would benefit from appropriate incentives to translate their science, yet at the same time they need structure and accountability," said Dr. Wamhoff.

Drs. Wamhoff's and Blackman's paradigm-shifting technology, which became the foundation of HemoShear, is the only technology of its kind that accurately replicates human organ system and disease biology in the laboratory.  HemoShear's human-relevant systems are being rapidly adopted by leading pharmaceutical and biotechnology companies to make better decisions and select drug candidates with superior efficacy and safety profiles.  Several institutes within the National Institutes of Health are funding programs with HemoShear, including the National Heart, Lung and Blood Institute; the National Institute of Diabetes and Digestive and Kidney Diseases; and the National Cancer Institute.

In the past forty years, there has been little progress in development of systems that accurately predict human response to new drug candidates.  As a result, more than 90% of new drugs fail in clinical trials, often after companies have spent hundreds of millions of dollars in late stage clinical trials.  The pharmaceutical industry has been consolidating and is seeking answers to reduce costs and improve success rates for new drugs.  HemoShear has repeatedly demonstrated its ability to predict new drug successes and failures.  The Company aims to improve the industry's return on capital, save billions of dollars by avoiding misdirected research, and bring innovative treatments to patients at lower cost.

Dr. Wamhoff's testimony and further information on the Committee's activities regarding the Small Business Technology Transfer program may be found at the following locations:

http://science.house.gov/sites/republicans.science.house.gov/files/documents/HHRG-113-SY14-WState-BWamhoff-20130724.pdf

http://science.house.gov/press-release/subcommittee-looks-improve-transfer-technologies-lab-market  

http://science.house.gov/hearing/subcommittee-research-and-technology-improving-technology-transfer-universities-research

About HemoShear, LLC

By applying physiologically accurate hemodynamics and biological transport to primary cell cultures, HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases for applications throughout drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health.  

For information about HemoShear, please visit www.hemoshear.com.


'/>"/>
SOURCE HemoShear, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HemoShear Announces Advancement of Predictive Drug Safety Systems
2. HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
3. HemoShear Relocates and Expands Operations to Historic Martha Jefferson Property in Charlottesville, Virginia
4. HemoShear Adds Industry Veterans Mehmood Khan and Fred Brown to Board of Managers
5. HemoShear Unveils In Vitro Steatosis System at Annual Meeting of the Association for the Study of Liver Diseases
6. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
7. SynCardia Co-Founder Honored with Pioneer in Transplantation Award at ISHLT
8. Key patent awarded to Adjuvance co-founders for pioneering method of producing rare vaccine component.
9. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
10. Revalesio Presents Data Showing RNS60 Alters Disease Progression in Animal Model of Alzheimers Disease Through the PI3k-Akt Pathway
11. Dr. Helen Fisher to Speak at Astellas Presents Executive Womens Day at the Constellation SENIOR PLAYERS Championship
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... 11, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it will release ... and host a conference call at 9:00am ET. The ... financial results and its strategy and outlook for the ... Erez Raphael , Chief Executive Officer, and ...
(Date:8/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... its Board of Directors has approved the payment of a ... 2017. The cash dividend ... October 27, 2017 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... , ... Maury Regional Health has announced a large-scale adoption of AccuVein vein ... Maury Regional Medical Center is making vein visualization part of their standard of care. ... more importantly, helps our staff members locate a vein that will provide good access ...
(Date:8/16/2017)... ... August 16, 2017 , ... With a new PD ... ultimately, a cure. , The grants are awarded through a competitive application process ... a wide array of backgrounds and expertise in all areas relevant to PD research. ...
(Date:8/16/2017)... Sacramento, CA (PRWEB) , ... August 16, 2017 ... ... ($10.99, paperback, 9781498499613; $5.99, eBook, 9781498499620    ) shares that during the time of a ... as reminding Strawn of God's love, and all the many ways God shows ...
(Date:8/16/2017)... ... August 16, 2017 , ... Women’s Excellence in ... pain. In addition to oncology services, the new center will specialize in ... heavy bleeding during menstruation), uterine fibroids, and uterine and pelvic adhesions (scar tissue). ...
(Date:8/16/2017)... ... ... pain afflicting 8 of 10 Americans at some point in their lives, some of us ... equally vexing condition stems from a variety of causes that can be effectively targeted by ... president of Atlantic Spine Center. , Nestled between your neck and lower back, the ...
Breaking Medicine News(10 mins):